Last updated on March 2020

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Brief description of study

The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-over-expressing and/or HER2-mutated advanced NSCLC subjects.

Clinical Study Identifier: NCT03505710

Find a site near you

Start Over

CHU Larrey

Toulouse, France
  Connect »